Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | CPB2 | Q96IY4 | 4/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.33 |
| ▸ | IDE | P14735 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13400091 | 1.00 | FOLH1 (0.49) | FOLH1TSHRKMT2APOLBL3MBTL1 | |
| SCHEMBL13400056 | 1.00 | FOLH1 (0.49) | FOLH1TSHRKMT2APOLBL3MBTL1 | |
| SCHEMBL14048647 | 0.95 | FOLH1 (0.58) | FOLH1TSHRCPB2SLC6A5 | |
| SCHEMBL21943867 | 0.94 | KMT2A (0.49) | FOLH1TSHRKMT2APOLBL3MBTL1 | |
| SCHEMBL14048625 | 0.94 | FOLH1 (0.44) | FOLH1TSHRKMT2APOLBL3MBTL1 | |
| SCHEMBL19594663 | 0.94 | KMT2A (0.49) | FOLH1TSHRKMT2APOLBL3MBTL1 | |
| SCHEMBL21844220 | 0.93 | KMT2A (0.50) | FOLH1TSHRKMT2APOLBL3MBTL1 | |
| SCHEMBL13515320 | 0.92 | FOLH1 (0.42) | FOLH1TSHRKMT2APOLBL3MBTL1 | |
| Trifluoroacetic Acid SCHEMBL1276507 | 0.92 | FOLH1 (0.45) | FOLH1TSHRKMT2APOLBL3MBTL1 | |
| SCHEMBL14930704 | 0.87 | TSHR (0.56) | FOLH1TSHRKMT2APOLBL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210299060-A1 | CO-DELIVERY OF NUCLEIC ACIDS FOR SIMULTANEOUS SUPPRESSION AND EXPRESSION OF TARGET GENES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2021-09-30 | — | — | US | disclosed |
| US-20190117799-A1 | STIMULI-RESPONSIVE NANOPARTICLES FOR BIOMEDICAL APPLICATIONS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-04-25 | — | — | US | disclosed |
| WO-2017173453-A1 | STIMULI-RESPONSIVE NANOPARTICLES FOR BIOMEDICAL APPLICATIONS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2017-10-05 | — | — | WO | disclosed |
| US-20170266187-A1 | Pemetrexed Polymeric Nanoparticles And Methods Of Making And Using Same | PFIZER INC. (US) | 2017-09-21 | — | — | US | disclosed |
| EP-2644594-B1 | Cancer Cell Targeting Using Nanoparticles | PFIZER (US) | 2017-08-23 | — | — | EP | disclosed |
| WO-2017137953-A1 | THERAPEUTIC NANOPARTICLES COMPRISING A THERAPEUTIC AGENT AND METHODS OF MAKING AND USING SAME | PFIZER INC. (US) | 2017-08-17 | — | — | WO | disclosed |
| EP-2644192-B1 | Cancer Cell Targeting Using Nanoparticles | PFIZER (US) | 2017-05-10 | — | — | EP | disclosed |
| US-9579386-B2 | Drug loaded polymeric nanoparticles and methods of making and using same | PFIZER INC. (US) | 2017-02-28 | — | — | US | disclosed |
| US-20160367481-A1 | CANCER CELL TARGETING USING NANOPARTICLES | PFIZER INC. | 2016-12-22 | — | — | US | disclosed |
| US-20160354320-A1 | DRUG LOADED POLYMERIC NANOPARTICLES AND METHODS OF MAKING AND USING SAME | PFIZER INC. | 2016-12-08 | — | — | US | disclosed |
| US-8273363-B2 | Cancer cell targeting using nanoparticles | BIND BIOSCIENCES, INC. (US) | 2012-09-25 | — | — | US | disclosed |
| US-8273363-B2 | Cancer cell targeting using nanoparticles | BIND BIOSCIENCES, INC. (US) | 2012-09-25 | — | — | US | disclosed |
| US-8206747-B2 | Drug loaded polymeric nanoparticles and methods of making and using same | BIND BIOSCIENCES, INC. (US) | 2012-06-26 | — | — | US | disclosed |
| US-8206747-B2 | Drug loaded polymeric nanoparticles and methods of making and using same | BIND BIOSCIENCES, INC. (US) | 2012-06-26 | — | — | US | disclosed |
| US-20120004293-A1 | Cancer Cell Targeting Using Nanoparticles | PFIZER INC. | 2012-01-05 | — | — | US | disclosed |
| US-20120004293-A1 | Cancer Cell Targeting Using Nanoparticles | PFIZER INC. | 2012-01-05 | — | — | US | disclosed |
| US-20110224288-A1 | Cancer Cell Targeting Using Nanoparticles | PFIZER INC. | 2011-09-15 | — | — | US | disclosed |
| US-20100068286-A1 | Drug Loaded Polymeric Nanoparticles and Methods of Making and Using Same | PFIZER INC. | 2010-03-18 | — | — | US | disclosed |
| US-20100068285-A1 | Drug Loaded Polymeric Nanoparticles and Methods of Making and Using Same | PFIZER INC. | 2010-03-18 | — | — | US | disclosed |
| US-20100068285-A1 | Drug Loaded Polymeric Nanoparticles and Methods of Making and Using Same | PFIZER INC. | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210299060-A1 | CO-DELIVERY OF NUCLEIC ACIDS FOR SIMULTANEOUS SUPPRESSION AND EXPRESSION OF TARGET GENES | AGO2, DCLRE1A, RNASE1 | FOLH1 3360/4885TSHR 1290/4885KMT2A 3921/4885 |
| US-20160354320-A1 | DRUG LOADED POLYMERIC NANOPARTICLES AND METHODS OF MAKING AND USING SAME | CD47, LPXN, CD44 | FOLH1 173/4885TSHR 4761/4885KMT2A 3389/4885 |
| US-20110224288-A1 | Cancer Cell Targeting Using Nanoparticles | CD47, EPCAM, CD44 | FOLH1 279/4885TSHR 4074/4885KMT2A 2333/4885 |
| US-20100068285-A1 | Drug Loaded Polymeric Nanoparticles and Methods of Making and Using Same | CD47, LPXN, CD44 | FOLH1 173/4885TSHR 4761/4885KMT2A 3389/4885 |
| US-20190117799-A1 | STIMULI-RESPONSIVE NANOPARTICLES FOR BIOMEDICAL APPLICATIONS | HSPA9, LRBA, AHSA1 | FOLH1 4319/4885TSHR 1397/4885KMT2A 4687/4885 |
| US-20100068286-A1 | Drug Loaded Polymeric Nanoparticles and Methods of Making and Using Same | LDHA, LDHB, LPXN | FOLH1 177/4885TSHR 4622/4885KMT2A 3569/4885 |
| US-20170266187-A1 | Pemetrexed Polymeric Nanoparticles And Methods Of Making And Using Same | MTHFD1, TYMP, FPGS | FOLH1 51/4885TSHR 4734/4885KMT2A 1912/4885 |
| US-20120004293-A1 | Cancer Cell Targeting Using Nanoparticles | CD47, EPCAM, CD44 | FOLH1 279/4885TSHR 4074/4885KMT2A 2333/4885 |
| US-20160367481-A1 | CANCER CELL TARGETING USING NANOPARTICLES | CD47, EPCAM, CD44 | FOLH1 279/4885TSHR 4074/4885KMT2A 2333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.